Maysaa Alakbaree

Dr. Maysaa Alakbaree

Bioinformatics, University of Information Technology and Communications, Baghdad, Baghdād, Iraq
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
PDF file
Maysaa AlakbareeMaysaa Alakbaree
Maysaa Alakbaree
SASayazwani Amran
Sayazwani Amran
MSMohd Shamsir
Mohd Shamsir
HAHaron Ahmed
Haron Ahmed
MHMuaawia Hamza
Muaawia Hamza
NLNurriza Ab Latif
Nurriza Ab Latif
Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme expressed in all cells of the body, where it catalyzes the first step of the pentose phosphate pathway (PPP) in the red blood cells. Deficiency of this enzyme causes hemolytic attacks as well as anemia that can be, fatal in certain cases. G6PD enzyme occurs in an active form in the cellular condition as a dimer or tetramer structure with bound glucose-6-phopsphate (G6P) and nicotinamide adenine dinucleotide phosphate (NADP+) molecules. However, a complete dimer structure of G6PD enzyme is not yet available in the Protein Data Bank. Developing of this complete structure is crucial for analyzing the mutations’ effect on G6PD structure. A preliminary study is reported by performing molecular docking to build a complete dimer structure of human G6PD enzyme using PyRx_Vina software version 0.9.8. Biovia Discovery Studio Client 2021 software version 0.8 was used to analyze and evaluate the protein-ligand interactions of the docking model, and the PyMOL molecular graphics system version 2.4.1 was carried out to visualize the final structure. The results of the successful docking exposed the best binding affinity (-7.2, -8.2) Kcal/mol of the catalytic and structural NADP+ in chain A, and (-6.7, and -7.9) Kcal/mol in chain (B) respectively. All structural analysis of G6PD enzyme should establish this model before performing any simulation since this research is a preliminary work and has not yet been published. This study will explain the molecular analysis of the G6PD variants induced by the deficiency of G6PD, thus providing new opportunities for the diagnosis and treatment of G6PD deficiency, in the absence of medication.

9 June 2022 in Gene Reports
Verified
Journal Article
Closed access
Maysaa AlakbareeMaysaa Alakbaree
Maysaa Alakbaree
SASayazwani Amran
Sayazwani Amran
MSMohd Shamsir
Mohd Shamsir
HAHaron H. Ahmed
Haron H. Ahmed
MHMuaawia Hamza
Muaawia Hamza
NLNurriza Ab Latif
Nurriza Ab Latif

20 April 2023 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
Maysaa AlakbareeMaysaa Alakbaree
Maysaa Alakbaree
AAAbbas Hashim Abdulsalam
Abbas Hashim Abdulsalam
HAHaron H. Ahmed
Haron H. Ahmed
FAFarah Hasan Ali
Farah Hasan Ali
MAMaysaa Alakbaree
Maysaa Alakbaree
SASyazwani Itri Amran
Syazwani Itri Amran

29 October 2023 in Journal of Contemporary Medical Sciences
Verified
Journal Article
Open access
Maysaa AlakbareeMaysaa Alakbaree
Maysaa Alakbaree
AAAli Abdulqader
Ali Abdulqader
AAAbbas Hashim Abdulsalam
Abbas Hashim Abdulsalam
MHMuaawia Ahmed Hamza
Muaawia Ahmed Hamza
SASyazwani Itri Amran
Syazwani Itri Amran
NLNurriza AB Latif
Nurriza AB Latif
G6PD deficiency (G6PDD) is associated with oxidative stress resulting from an imbalance between reactive oxygen species (ROS) production and the body's ability to counteract. In this review, we explore the adverse effects of G6PDD on diverse physiological processes and disease outcomes. Past studies have demonstrated the association between G6PDD and various other diseases, indicating a link between G6PDD to heightened oxidative stress by accelerating virus replication, worsening infection severity, and weakening the body's defense mechanisms. Such stress is critical in the destruction of red blood cells (RBCs) during infections and has a detrimental impact on redox signaling, ultimately impacting cell health and promoting cancer development. Furthermore, it impairs endothelial function by lowering the nitric oxide (NO) level and increasing stress, resulting in detrimental cardiac consequences and reduced myocardial antioxidant capacity. Because ROS contributes to inflammation, this imbalance causes conditions such as early atherosclerosis. It also compromises the functionality of NO-regulated bronchodilators and conditions such as G6PDD exacerbate the risks of kidney damage. Elevated ROS levels can also induce harm in retinal tissues, blood vessels, brain cells, and Beta-cells, hence quickening the progression of diseases like Diabetic Retinopathy. Furthermore, oxidative stress plays a significant role in cerebral ischemic pathogenesis, contributing to neurodegenerative disorders. Additionally, decreased NADPH level is vital for NO synthesis as it can impact blood vessel relaxation and can potentially lead to ischaemic priapism. Investigating the association between G6PDD and other medical conditions is crucial as it helps to identify possible approaches to mitigate oxidative stress, thereby preventing associated complications and diseases, particularly in situations where current treatment options are insufficient.

1 January 2022 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
PDF file
Maysaa AlakbareeMaysaa Alakbaree
Maysaa Alakbaree
ZZZarita Zakaria
Zarita Zakaria
HAHaron Ahmed
Haron Ahmed
NZNurliyana Zawawi
Nurliyana Zawawi
Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide, and thrombosis is the most common of the three major cardiovascular diseases: ischemic heart disease (acute coronary syndrome), stroke, and venous thromboembolism (VTE). In this study, an attempt to investigate a new potential pathogenic bacterium from clinical source (throat swab) that produced fibrinolytic enzymes and the activity of the enzymes on blood clot formation was made. For the bacterial screening, two different media were used, which are blood agar and skimmed milk agar. Next, for the primary identification of bacterial genus, gram staining, and catalase test was done, followed by 16S rRNA to identify the isolated bacteria rapidly and accurately, which include genomic DNA (gDNA) isolation, PCR amplification, nucleotide sequencing, gel electrophoresis, nucleotide sequence analysis, and phylogenetic tree construction. Apart from that, protein assay was done by Lowry's method, and the determination of the proteolytic activity was done by the caseinolytic analysis, followed by the in vitro clot lysis activity of the enzymes. Initially, three main colonies were found, which was differed in the pigmentation of the colony. However, only YS1 strain showed a positive β-hemolytic pattern on blood agar and clear hydrolysis zones on skimming milk agar. Therefore, YS1 strain was chosen for further fibrinolytic analysis. Moreover, bacterial sequencing confirmed the YS1 strain gene sequence was found 100 % similarity with the members of the highly associated genera Staphylococcus aureus and was designated as Staphylococcus aureus S1. The total amount of protein in S. aureus S1 was 0.57 (mg/ml), while the caseinolytic activity and the specific activity were 1.43 (U/ml). The highest 46% of clot lysis by staphylokinase after 4 hrs. incubation was observed.

1 January 2022 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
PDF file
HAHaron Ahmed
Haron Ahmed
Maysaa AlakbareeMaysaa Alakbaree
Maysaa Alakbaree
AYAbdullahi Yarima
Abdullahi Yarima
Troponin I (TnI) is the inhibitory subunit of the troponin complex in the sarcomere thin filament of the striated muscle and plays a critical role in the calcium regulation of contraction and relaxation. However, its 3D structure remains unknown until now. Thus, modeling and understanding of this protein are significant. Modeling the predicted 3D structure helps to analyze the function of this protein. The amino acid sequence of Troponin I, slow skeletal muscle was retrieved from the Uniprot database (UniProt ID: P19237). Prediction of protein secondary structure was obtained using the CFSSP website (Chou & Fasman Secondary Structure Prediction Server), while for homology modeling, Phyre2 software was used. While PyMol and Chimera visualization software was used for The structural comparison between the protein predicted model and the templates. Troponin I, the Three-dimensional (3D) structure of slow skeletal muscle is innovative to the extent that it has no protein modeling structure among all organisms that contained such protein up to the present time. Troponin I, slow skeletal muscle was obtained from the UniProt database (P19237). BLASTp in the NCBI database was carried out to identify resemble sequence, The secondary structure prediction analysis showed 165 residues, 88.2% involved in the formation of the helix, 76 residues involved in the formation of beta-sheet and 25 residues, 13.4% involved in the formation of turn CFSSP server (Chou & Fasman Secondary Structure Prediction Server). Three different model evaluation web servers (PROCHECK, Verify 3D, and ERRAT). 89% of residues had located in favored regions, 8.1 % of residues had situated in additional allowed regions, and 1.2% residues in generously allowed regions 1.7% disallowed regions. This indicating the model generated has good stereochemical quality with accurate structure geometry. Troponin I, slow skeletal muscle is so novel to an extent that it has no three-dimensional (3D) structure among all organisms that contained such protein up to the present time. So, in this study, the predicted 3D model was compared with a template, due to the absence of any known 3D structure, and provide useful information to this protein since this protein is essential in the medical sector.